Short Interest in Revelation Biosciences, Inc. (NASDAQ:REVB) Increases By 87.5%

Revelation Biosciences, Inc. (NASDAQ:REVB) was the target of a large growth in short interest in the month of May. As of May 15th, there was short interest totaling 34,510 shares, a growth of 87.5% from the April 30th total of 18,409 shares. Currently, 0.9% of the company’s stock are short sold. Based on an average daily trading volume, of 81,197 shares, the days-to-cover ratio is presently 0.4 days.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Sabby Management LLC increased its position in Revelation Biosciences by 192.5% during the fourth quarter. Sabby Management LLC now owns 605,702 shares of the company’s stock worth $484,000 after buying an additional 398,651 shares during the period. Armistice Capital LLC increased its position in Revelation Biosciences by 442.8% during the fourth quarter. Armistice Capital LLC now owns 434,272 shares of the company’s stock worth $347,000 after buying an additional 354,272 shares during the period. Finally, Geode Capital Management LLC acquired a new position in Revelation Biosciences during the fourth quarter worth approximately $27,000. Institutional investors and hedge funds own 12.80% of the company’s stock.

Revelation Biosciences Stock Down 0.5%

REVB opened at $1.09 on Tuesday. The firm has a market cap of $4.26 million, a price-to-earnings ratio of -0.03 and a beta of -0.14. Revelation Biosciences has a 52 week low of $0.88 and a 52 week high of $13.80. The business’s 50 day moving average is $1.13 and its two-hundred day moving average is $2.16.

Revelation Biosciences (NASDAQ:REVB) last released its quarterly earnings results on Thursday, May 7th. The company reported ($2.71) EPS for the quarter, missing the consensus estimate of ($1.15) by ($1.56). Equities analysts expect that Revelation Biosciences will post -4.99 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut Revelation Biosciences from a “sell (e+)” rating to a “sell (e)” rating in a research note on Wednesday, May 13th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.